ArticleHealth affairs scholar2025
Inflation reduction act impact on pharmaceutical investment: insights from investor interviews.
Article in Health affairs scholar, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Understanding biopharmaceutical investment decision-making: how does Congressional Budget Office's model compare to investor insights?Health affairs scholar · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: There is limited direct measurement of whether the Inflation Reduction Act (IRA) is beginning to influence investment strategy and decisions. Methods: Using a standardized guide, we interviewed life science investors from a range of stages, investment sizes, and fund types to explore how incentives under the IRA have impacted investment decisions. Results: We interviewed 31 active investors. Over 90% had discussed the law within their firm. While 71% reported a lack of firm-wide consensus as to the IRA's precise potential impacts, 87% reported that the IRA was making it more challenging to bring innovative new medicines to market. All but one investor reported they were more likely to consider a larger launch indication for products they invest in, and 77% reported the IRA influenced small molecule investing. Conclusion: Early signals of IRA impact on investor strategy include favoring a larger population launch and reduced small molecule investing. Noting stated preference and other study limitations, investors signaled continued interest in certain high Medicare utilization drugs. Buy-side investment impacts remain understudied.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.